UBS Group
CRXTW

UBS Group’s Clarus Therapeutics Holdings, Inc. Warrants CRXTW Stock Holding History

UBS Group’s Portfolio CRXTW Stock Details CRXTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-22,242
Closed -$2K – 11710
2022
Q2 		$2K Buy
+22,242
New +$2.19K ﹤0.01% 9763

Other funds holding CRXTW

MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return

UBS Group's CRXTW Position: Q3 2022 in Review

UBS Group sold out of Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) in Q3 2022, closing a stake of 22,242 shares — an estimated $2K sold.

UBS Group first reported a position in CRXTW in Q2 2022 and held it in 1 quarter. The position peaked at $2K in Q2 2022. 5 funds tracked by Wall St. Rank hold CRXTW as of Q3 2022.

  • UBS Group reported no remaining Clarus Therapeutics Holdings, Inc. Warrants position as of Q3 2022 after selling out during the quarter.
  • UBS Group sold 22,242 Clarus Therapeutics Holdings, Inc. Warrants shares in Q3 2022, an estimated $2K.
  • UBS Group first reported a position in Clarus Therapeutics Holdings, Inc. Warrants in Q2 2022 and held it in 1 quarter.
  • UBS Group's Clarus Therapeutics Holdings, Inc. Warrants position peaked at $2K in Q2 2022.
  • 5 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Warrants as of Q3 2022.

Based on UBS Group's 13F filing for Q3 2022, filed 10 Nov 2022.